News for PFIZER INC (PFECL.SN)

The preventive healthcare technologies and services market size was valued at USD 284.42 billion in 2024 and is projected to reach USD 668.15 billion by 2032, expanding at a robust CAGR of 11.28%…

PALM BEACH, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The market for abuse-deterrent opioids is still developing, but it's esti

CARDIFF, UNITED KINGDOM / ACCESS Newswire / June 18, 2025 / When it comes to type 1 diabetes, treating this chronic condition can be difficult. After all, with

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash f...

Option traders are showing a moderately bearish outlook on Pfizer (PFE), as the stock saw a decline of $0.24, currently trading around $24.16. The options tradi

(Bloomberg) -- The Trump administration is discussing policies that would make it harder and more expensive for pharmaceutical companies to advertise directly to patients, in a move that could disrupt more than $10 billion in annual ad spending.Most Read from BloombergSecurity Concerns Hit Some of the World’s ‘Most Livable Cities’As Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention SpaceAs American Architects Gather in Boston, Retrofits Are All the RageHow E-Scooters Con

Insights from the First Quarter of 2025 N-PORT Filing Vanguard Health Care Fund (Trades, Portfolio) recently submitted its N-PORT filing for the first quarter

Pfizer (PFE) saw its shares decrease by $0.20, trading around $24.34 recently. The stock's options activity was steady, with approximately 78,000 contracts exch

Key Takeaways: Pfizer's Talzenna faces limitations after FDA's rejection for wider use. Analysts suggest a 16.43% potential upside for Pfizer shares with

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

**media[654537]**

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now.

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers, had a meeting with the Trump administration to talk about reducing US drug prices. However, Pfizer’s chief executive, Albert Bourla, mentioned that no commitments have been agreed upon. President Trump ordered drugmakers last […]

WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. ( XLO), a clinical-stage biotechnology company discovering and developing tumor-act

Key Insights: Despite regulatory shifts, Pfizer's stock remains stable, indicating minimal market impact. Analysts predict a 17.55% upside potential for

CEO of Pfizer raises concerns about U.S. drug pricing reforms. Analysts predict a potential upside for Pfizer Inc.'s stock. Brokerage consensus maint

(Bloomberg) -- This year’s stock market turbulence has punished ordinary investors. But for the wealthy, it’s opened up fresh opportunities to convert equity swings into tax breaks — fueling a growing Wall Street business that turns volatility into a financial advantage. Most Read from BloombergTrump Said He Fired the National Portrait Gallery Director. She’s Still There.NYC Mayoral Candidates All Agree on Building More Housing. But Where?Senator Calls for Closing Troubled ICE Detention Facility

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and why it is a Buy.

Health and Human Services Secretary Robert F. Kennedy Jr.’s decision to dismiss all 17 members of the ACIP has triggered a decline in shares of pharmaceutical companies like Novavax (NVAX), Pfizer (PFE), and Merck (MRK) in after-hours trading. Kennedy’s overhaul, aimed at restoring public trust in vaccine science, raises concerns…